Loading
Loading…
Loading…
| # | Company | Amount | Rank | Status |
|---|---|---|---|---|
| 1 | H1₹89.36Admitted-Finance | H1 | Admitted-Finance | |
| 2 | H2₹82.96−₹6.40 (7.16%)Admitted-Finance | H2 | Admitted-Finance | |
| 3 | H3₹73.88−₹15.48 (17.3%)Admitted-Finance | H3 | Admitted-Finance | |
| 4 | Rejected-Technical SURVEY NO 144 A JAROD SAMLAYA ROAD VILL HARIPURA TAL SAVLI DIST VADODARA GUJARAT INDIA 391520 | VADODARA | VADODARA | GUJARAT | 391520 | - | Rejected-Technical As per Evaluation Summary | |
| 5 | Rejected-Technical | - | Rejected-Technical As per Evaluation Summary |
| Sl No | Description | Qty | Unit | Mylan Laboratories Limited H2 | HETERO LABS LIMITED H3 | NATCO PHARMA LIMITED H1 |
|---|---|---|---|---|---|---|
| 1.00ANTI TB DRUGS | ||||||
| 1.01 | Sofosbuvir 400 mg + Velpatasvir 100 mg | 24,63,132 | Tablets | 74.07 ₹82.96 | 65.96 ₹73.88 Lowest | 79.79 ₹89.36 |
Tender Value
Refer Docs
EMD Value
₹18.5 L
Closing Date
8 Jan 2024, 3:00 pmClosed
DG and CEO
CMSS New Delhi
Tender for Procurement of Hepatitis C Drugs for NVHCP
2023_CMSS_784074_1
CMSS/PROC/2023-24/NVHCP/055
Open Tender
Drugs and Pharmaceutical Products
Supply
60 days
CMSS New Delhi
Please refer Tender documents.
2 documents required · 2 mandatory
₹0
₹18.5 L
Yes
CMSS New Delhi
30 Apr 2024
6 Dec 2023
9 Jan 2024
6 Dec 2023
8 Jan 2024
20 Dec 2023
6 Dec 2023 - 13 Dec 2023
13 Dec 2023
ANTI TB DRUGS
Sofosbuvir 400 mg + Velpatasvir 100 mg
Mylan Laboratories Limited
HETERO LABS LIMITED
stage.html
html • 0.03 MB
tech_bid_open.pdf
tech_eval.pdf
fin_bid_open.pdf
boq_comp_chart.xlsx
xlsx
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.03 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .